Article Text

Download PDFPDF

725 Preliminary results of a prospective pilot study using CD8 ImmunoPET imaging to evaluate the immune response to radiation therapy (ELIXR)
  1. Claire Hao1,
  2. Colton Ladbury1,
  3. Paul Frankel1,
  4. William T Watkins1,
  5. Sumanta Pal1,
  6. Jeffrey Wong1,
  7. Saro Manoukian1,
  8. Maria Parayno1,
  9. William Le2,
  10. Gareth Smith2,
  11. Michael Ferris2,
  12. Kristin Schmiedehausen2,
  13. Anna Wu1,2 and
  14. Savita Dandapani1
  1. 1City of Hope, Duarte, CA, USA
  2. 2ImaginAb Inc, Inglewood, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Radiation therapy (RT) may produce immunomodulatory effects that can interact with immunotherapy. Our pilot study (NCT05371132) uses 89Zr-Df-crefmirlimab, a radiolabeled CD8-specific minibody, to image intratumoral changes in CD8+ T cell activity during and after RT. Here, we present the results of our first four patients.

Methods Eligible patients have no change in systemic treatment within two months prior to RT and no splenic disorders. Patients receive a 1 mCi dose of 89Zr-Df-crefmirlimab before and 1–2 weeks after a 5-fraction RT course. Each dose is followed by a whole-body positron emission tomography (PET) scan, and each radiation fraction is followed by a region-of-interest PET. Maximum standardized uptake values (SUVmax) of lesions are extracted from each CD8 ImmunoPET scan.

Results 3 metastatic renal cell carcinoma (mRCC) patients and 1 diffuse large B-cell lymphoma (DLBCL) patient have completed treatment. Median age was 64 years (range 61–65). Concurrent therapies included cabozantinib, nivolumab, and an experimental chemotherapy XL092 (table 1). The mRCC patients (P1-P3) received stereotactic body RT (30–40 Gy in 5 fractions) to one metastatic site. The DLBCL patient (P4) received RT (20 Gy in 5 fractions) to two lesions in the legs, in the bridging setting prior to chimeric antigen receptor (CAR) T-cell therapy. No toxicities attributable to the CD8 PET tracer were observed.

Mean peak increase in SUVmax of the treated lesion in P1-P3 was 14.5 ± 8.1 (standard deviation). Mean size reduction by longest diameter of P1-P3 was 36.3% ± 20.2% (standard deviation). Each patient’s results are included in table 1. In P1, a normal lymph node saw an unusual 4.4 increase in SUVmax post-RT. At 8-month follow-up, this was found to have developed into a lesion (figure 1).

In P4, peak increase in SUVmax was 1.2 and 2.7 in the left and right leg treated lesions, respectively. Images are shown in figure 2. Two non-target lesions proximal to the left leg target lesion that received ~1% of the dose achieved an increase in CD8 SUVmax of 1.2 and 1.7 during radiation and resolved post-RT pre-CAR T. CD8 ImmunoPET taken 7 days post-CAR T infusion did not demonstrate any significant CD8 PET signal. All lesions resolved by day 30 post-CAR T on FDG PET imaging.

Conclusions Increase in intratumoral CD8+ T cell activity was observed during RT in mRCC and lymphoma patients. Follow-up may reveal the prognostic implications of visualizing the immunogenic effects of radiation using CD8 ImmunoPET.

Trial Registration NCT05371132

Ethics Approval This clinical trial was approved by the City of Hope Institutional Review Board (IRB) and has IRB number 21221. All trial participants provided informed consent prior to taking part in this study.

Abstract 725 Table 1

Change in CD8 ImmunoPET SUVmax of treated lesions and reponse

Abstract 725 Figure 1

Images showing a hilar lymph node that displayed notable increase in CD8 PET SUVmax post-radiation, which developed into a metastasis 8 months later

Abstract 725 Figure 2

CD8 PET imaging of the irradiated lesion in the right leg of a lymphoma patient who received bridging radiation before CAR T cell infusion

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.